GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Cash Flow from Operations

Novo Integrated Sciences (Novo Integrated Sciences) Cash Flow from Operations : $-4.95 Mil (TTM As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Feb. 2024, Novo Integrated Sciences's Net Income From Continuing Operations was $-2.75 Mil. Its Depreciation, Depletion and Amortization was $0.57 Mil. Its Change In Working Capital was $-0.60 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.15 Mil. And its Cash Flow from Others was $0.92 Mil. In all, Novo Integrated Sciences's Cash Flow from Operations for the three months ended in Feb. 2024 was $-1.71 Mil.


Novo Integrated Sciences Cash Flow from Operations Historical Data

The historical data trend for Novo Integrated Sciences's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Cash Flow from Operations Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.82 -0.44 -1.03 -5.88 -2.24

Novo Integrated Sciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.86 -0.23 -2.15 -1.71

Novo Integrated Sciences Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Novo Integrated Sciences's Cash Flow from Operations for the fiscal year that ended in Aug. 2023 is calculated as:

Novo Integrated Sciences's Cash Flow from Operations for the quarter that ended in Feb. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Integrated Sciences  (NAS:NVOS) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Novo Integrated Sciences's net income from continuing operations for the three months ended in Feb. 2024 was $-2.75 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Novo Integrated Sciences's depreciation, depletion and amortization for the three months ended in Feb. 2024 was $0.57 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Novo Integrated Sciences's change in working capital for the three months ended in Feb. 2024 was $-0.60 Mil. It means Novo Integrated Sciences's working capital declined by $0.60 Mil from Nov. 2023 to Feb. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Novo Integrated Sciences's cash flow from deferred tax for the three months ended in Feb. 2024 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Novo Integrated Sciences's cash from discontinued operating Activities for the three months ended in Feb. 2024 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Novo Integrated Sciences's asset impairment charge for the three months ended in Feb. 2024 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Novo Integrated Sciences's stock based compensation for the three months ended in Feb. 2024 was $0.15 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Novo Integrated Sciences's cash flow from others for the three months ended in Feb. 2024 was $0.92 Mil.


Novo Integrated Sciences Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Executives
Sarfaraz Ali director C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva director 115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope director 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias director 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor director 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione director, 10 percent owner, officer: Chief Executive Officer 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt director, 10 percent owner 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David director, officer: President 10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald officer: Chief Accounting Officer 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters director 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse officer: secretary 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden officer: President & CEO 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo director 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724